Genzyme/Ilex merger
Executive Summary
Federal Trade Commission issues second request for information on Genzyme/Ilex merger. FTC is investigating whether Ilex' leukemia agent Campath, which is being studied by independent researchers as a transplant treatment, would overlap with Genzyme's renal transplant agent Thymoglobulin. Companies announced Genzyme's $1 bil. acquisition of Ilex on Feb. 26 (1"The Pink Sheet" March 1, 2004, p. 12)...
You may also be interested in...
Genzyme hope to “disentangle” Schering Campath deal
Genzyme proposes plan to FTC that will "disentangle" Schering from a marketing agreement for Ilex' leukemia agent Campath, Genzyme Senior VP Thomas DesRosier says. FTC is reviewing Genzyme's proposed $1 bil. acquisition of Ilex and is investigating whether Campath, which is being studied by independent researchers as a transplant treatment, would overlap with Genzyme's renal transplant agent Thymoglobulin (1"The Pink Sheet" May 3, 2004, In Brief). Genzyme expects to reach an agreement in principle with FTC shortly and maintains the deal can be closed this summer...
Genzyme Enters Oncology Market Via $1 Bil. Acquisition Of Ilex
Genzyme will pay $1 bil. for its first marketed oncology therapeutic agent through the acquisition of Ilex Oncology
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.